RecruitingNot ApplicableNCT07599241

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Sponsor

Cairo University

Enrollment

40 participants

Start Date

Mar 15, 2026

Study Type

INTERVENTIONAL

Conditions

Non-Alcoholic Fatty Liver Disease Subclinical hypothyroïdism Primary Open Angle Glaucoma

Summary

additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated

Eligibility

Sex: FEMALEMin Age: 65 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called physical activity and usual care for people with non-alcoholic fatty liver disease, primary open angle glaucoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 65 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALphysical activity

hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month

OTHERusual care

hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only

Locations(1)

Cairo University

Dokki, Giza Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07599241

Related Trials

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT0682273827 locations

PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

NCT0723559211 locations

Hydrus® Microstent New Enrollment Post-Approval Study

NCT0455352322 locations

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

NCT038840751 location

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

NCT0692004330 locations